Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861QSatoshi Watanabe, Kunihiko Kobayashi, Akira Inoue et al.|Journal of Thoracic Oncology|2014Cited by 204
First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studiesNaoto Morikawa, Akihiko Gemma, Yuji Minegishi et al.|Expert Opinion on Pharmacotherapy|2015Cited by 33
Randomized Phase II Trial Comparing Carboplatin Plus Weekly Paclitaxel and Docetaxel Alone in Elderly Patients With Advanced Non-Small Cell Lung Cancer: North Japan Lung Cancer Group Trial 0801Makoto Maemondo, Toshihiro Nukiwa, Akira Inoue et al.|The Oncologist|2014Cited by 21
First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study).Yuji Minegishi, Akihiko Gemma, Makoto Maemondo et al.|Journal of Clinical Oncology|2010Cited by 20
A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027Yuji Minegishi, Akihiko Gemma, Ou Yamaguchi et al.|BMC Cancer|2021Cited by 18